Further preclinical studies are warranted to optimize dosing regimen, including in combination with antibiotics, and at delayed time points after MCAO and in aged and co‐morbid animals, to better understand the translational potential of IgM‐IVIg as an anti‐infective agent for stroke patients. This evidence concerns the gene CD40LG and stroke disorder.